ARS Pharmaceuticals: Investors May Lead Securities Fraud Lawsuit
ROSEN LAW FIRM reminds purchasers of ARS Pharmaceuticals, Inc. (SPRY) securities of a potential lead plaintiff opportunity. The deadline to file for lead plaintiff status is October 5.
ROSEN LAW FIRM, a global investor rights law firm, has notified investors who purchased ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) securities between March 9, 2026, and June 24, 2026. According to the firm, these investors may have the opportunity to lead a securities fraud class action lawsuit against SPRY.
The law firm has initiated an investigation into potential securities law violations concerning ARS Pharmaceuticals. The investigation will examine allegations of misleading statements made by the company to investors.
Interested investors must file a motion to be appointed lead plaintiff by October 5, 2026. Missing this deadline may impair investors' ability to participate in the lawsuit's recovery.
Rosen Law Firm specializes in securities litigation and corporate finance. The firm encourages all affected investors to contact them to discuss their legal rights and options.